GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort ... - FiercePharma

GlaxoSmithKline's Advair loses share to AstraZeneca's aggressive Symbicort ... FiercePharma Advair's throne is slowly eroding. With stepped-up competition from rival lung drugs -- including AstraZeneca's Symbicort -- GlaxoSmithKline's top-selling product, with $7.7 billion in 2012 sales, is losing share in the U.S.. As Bloomberg reports ...

Source: http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGXUhBQvD4-4IPoohIQ7Ab9HwIbBA&url=http://www.fiercepharma.com/story/glaxosmithklines-advair-loses-share-astrazenecas-aggressive-symbicort-disco/2014-02-04

printable vouchers offers online coupon online coupon promo online coupon companies